GlassScriptPhysician profile
Kimberly E Schrock
NPI 1053745729
$5,122.42
in general payments reported to CMS, 2019-2025
22 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.50 · 2022: $218 · 2023: $997 · 2024: $2,022 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,609 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,609.36 |
| Education | $280.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $996.36 | 2023-2025 | Airsupra, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $563.99 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $443.67 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Genentech USA, INC. | $435.90 | 2023-2025 | Xolair |
| Csl Behring | $420.87 | 2023-2025 | Hizentra, Andembry, Haegarda |
| Novartis Pharmaceuticals Corporation | $383.25 | 2022-2025 | |
| Glaxosmithkline, LLC. | $319.00 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $264.15 | 2022-2025 | |
| Amgen INC. | $224.70 | 2023-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $219.65 | 2023-2025 | Orladeyo |
| Pharming Healthcare, INC. | $180.73 | 2024-2025 | Ruconest |
| Sanofi-Aventis U.S. LLC | $156.97 | 2021-2025 | |
| Pfizer INC. | $124.99 | 2023-2025 | |
| Hospira, INC. | $89.18 | 2024-2025 | |
| Leo Pharma INC. | $76.83 | 2022-2024 | Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $65.24 | 2024-2025 | Xembify, Prolastin-C Liquid |
| Lilly USA, LLC | $48.63 | 2024-2025 | Ebglyss |
| Optinose US, INC. | $31.38 | 2023-2024 | |
| Ars Pharmaceuticals Operations, INC. | $31.16 | 2025 | Neffy |
| Paratek Pharmaceuticals, INC. | $17.34 | 2025 | Xhance |
| Bayer Healthcare Pharmaceuticals INC. | $14.33 | 2023 | |
| Abbvie INC. | $14.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Schrock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.